Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pivotal Therapeutics, a specialty pharmaceutical company, has received its product license and NPN number for Omazen from Health Canada.
Subscribe to our email newsletter
The move by the agency will authorize the sale of product in the Canadian market.
Omazen is EPA:DHA fatty acid formulation, which elevates Omega-3 fatty acid levels and helps maintain good health.
According to the Natural Health Products Directorate (NHPD), Omazen is compliant with Natural Health Products Regulations.
Pivotal Therapeutics chair and chief scientific officer George Jackowski said their Omega-3 formulation is different as proven by the clinical data.
"As consumers increase their awareness of interpreting product label information they will realize the superiority of Omazen," Jackowski added.